MMP

Therapie der gastroösophagealen Refluxerkrankung Übersicht
MMP
Aktuelle und zukünftige Therapien der
gastroösophagealen Refluxerkrankung
Martin Storr, München
Literatur
1.Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical
application. Ann Intern Med 1983;98:86–95.
2.Beaumont H, Smout A, Aanen M, et al. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations
and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther 2009;30:937–46.
3.Boeckxstaens GE, Rydholm H, Lei A, et al. Effect of lesogaberan, a
novel GABA-receptor agonist, on transient lower esophageal sphincter
relaxations in male subjects. Aliment Pharmacol Ther 2010;31:1208–17.
4.Boeckxstaens GE. Emerging drugs for gastroesophageal reflux disease.
Expert Opin Emerg Drugs 2009;14:481–91.
5.Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation
of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682–6.
6.Camilleri M, Dubois D, Coulie B, et al. Prevalence and socio­economic
impact of upper gastrointestinal disorders in the United States: results
of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol
2005;3:543–52.
7.Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and
symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798–810.
8.Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:208–14.
9.Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-­oesophageal reflux disease: a systematic review. Gut
2005;54:710–7.
10.DeVault KR, Castell DO. ACG treatment guideline: updated guidelines
for the diagnosis and treatment of gastroesophageal reflux disease. Am J
Gastroenterol 1999;94:1434–42.
11. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs.
doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007;26:1333–44.
12.Drossman DA. The functional gastrointestinal disorders and the
Rome III process. Gastroenterology 2006;130:1377–90.
13.Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of
H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology
2002;122:625–32.
14.Fock KM, Ang TL. Dexlansoprazole, a modified release formulation of
an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Curr Opin Investig Drugs 2008;9:1108–15.
15.Gaspar A, Ribeiro S, Nabais S, Rocha S, et al. Proton pump inhibitors
in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol 2010;29:1511–20.
16.Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J
Gastroenterol 2010;105:1266–75.
17.Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump
inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol
2009;104:1541–5.
18.Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents
with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol
Nutr 2002;35(Suppl 4):S327–35.
19.Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009;30:331–42.
20.Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological
Association Institute technical review on the management of gastro­
esophageal reflux disease. Gastroenterology 2008;135:1392–1413,
1413.e1-5. Epub 2008 Sep 16.
21.Keller J, van der Voort I, Pehl C, et al. Durchführung und Interpretation der Ösophagusmanometrie: Empfehlungen der Deutschen Gesellschaften für Neurogastroenterologie und Motilität (DGNM), für Verdauungs- und Stoffwechselerkrankungen (DGVS) und für Allgemein- und
Viszeralchirurgie (DGAV). Z Gastroenterol 2009;47:830–45.
22.Klotz U. Proton pump inhibitors – their pharmacological impact on the
clinical management of acid-related disorders. Arzneimittelforschung
2009;59:271–82.
23.Koretz RL, Rotblatt M. Complementary and alternative medicine in
gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol
Hepatol 2004;2:957–67.
24.Koury SI, Stone CK, La Charite DD. Omeprazole and the development
of acute hepatitis. Eur J Emerg Med 1998;5:467–9.
25.Kuipers EJ. Proton pump inhibitors and Helicobacter pylori gastritis:
friends or foes? Basic Clin Pharmacol Toxicol 2006;99:187–94.
26.Lacy BE, Paquette L, Robertson DJ, et al. The clinical utility of eso­
phageal manometry. J Clin Gastroenterol 2009;43:809–15.
27.Lux G, Van Els J, The GS, et al. Ambulatory oesophageal pressure, pH
and ECG recording in patients with normal and pathological coronary angiography and intermittent chest pain. Neurogastroenterol Motil
1995;7:23–30.
28.Malfertheiner P, Gerards C. Helicobacter pylori infection and gastrooesophageal reflux disease: coincidence or association? Baillieres Best
Pract Res Clin Gastroenterol 2000;14:731–41.
29.Meining A, Classen M. Gastroösophageale Refluxkrankheit. Internist
1998;39:1215–22.
30.Meining A, Classen M. The role of diet and lifestyle measures in the
pathogenesis and treatment of gastroesophageal reflux disease. Am J
Gastroenterol 2000;95:2692–7.
31.Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with
gastroparesis: a preliminary report. Dig Dis Sci 2008;53:2621–6.
Priv.-Doz. Dr. med. Martin Storr, Medizinische Klinik II der Ludwig-MaximiliansUniversität München, Klinikum Großhadern, Marchioninistraße 15,
81377 München, E-Mail: grdoc@gmx.com
MMP 34. Jahrgang 12/2011
1
MMP
Übersicht Therapie der gastroösophagealen Refluxerkrankung
32.Nguyen HN, Silny J, Matern S. Multiple intraluminal electrical impedancometry for recording of upper gastrointestinal motility: current results and further implications. Am J Gastroenterol 1999;94:306–17.
33.Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter,
­double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514–20.
34.Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric
acid breakthrough on omeprazole: a controlled study in normal subjects.
Gastroenterology 1998;115:1335–9.
35.Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at
night improve gastroesophageal reflux disease symptoms for patients on
proton pump inhibitor therapy. Dis Esophagus 2005;18:370–3.
36.Raiha IJ, Impivaara O, Seppala M, Sourander LB. Prevalence and
­characteristics of symptomatic gastroesophageal reflux disease in the
elderly. J Am Geriatr Soc 1992;40:1209–11.
37.Richter JE, Sabesin S, Kogut D, et al. Omeprazole versus ranitidine or
ranitidine/metoclopramide in poorly responsive symptomatic GERD.
Am J Gastroenterol 1996;91:1766–72.
38.Ruigomez A, Rodriguez LA, Wallander MA, et al. Endoscopic findings in a cohort of newly diagnosed gastroesophageal reflux disease
patients registered in a UK primary care database. Dis Esophagus
2008;21:251–6.
39.Sachs G, Shin JM, Howden CW. Review article: the clinical
pharmaco­logy of proton pump inhibitors. Aliment Pharmacol Ther
2006;23(Suppl 2):2–8.
40.Schindlbeck N. Diagnosis and clinical course in gastroesophageal reflux. Fortschr Med 1996;114:31–4.
41.Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux
moni­toring: review and consensus report on detection and definitions of
acid, non-acid, and gas reflux. Gut 2004;53:1024–31.
42.Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients
with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005;54:449–54.
43.Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19
genotype in a large nationwide cohort of acute myocardial infarction:
results from the French Registry of Acute ST-Elevation and Non-STElevation Myocardial Infarction (FAST-MI) registry. Circula­tion
2011;123:474–82.
44.Smout AJ. Review article: The measurement of non-acid gastro-oesophageal reflux. Aliment Pharmacol Ther 2007;26(Suppl 2):7–12.
*2
MMP 34. Jahrgang 12/2011
45.Storr M, Allescher HD. Barrett-Ösophagus, gastroösophagealer Reflux
und Helicobacter pylori als Risikofaktoren für das Adenokarzinom der
Speiseröhre. Verdauungskrankh 2000;18:57–62.
46.Storr M, Allescher HD. Motilitätsmodifizierende Pharmaka. Internist
2000;12:1318–30.
47.Storr M, Allescher HD. Reflux disease as a motility disorder: treatment
alternatives to acid suppression. Gastroenterology 2010;139:2207–9.
48.Storr M, Meining A, Allescher HD. Pathophysiology and pharmaco­
logical treatment of gastroesophageal reflux disease. Dig Dis
2000;18:93–102.
49.Storr M, Meining A, Allescher HD. Pharmacoeconomic issues of the
therapy of gastroesophageal reflux disease. Exp Opin Pharmacother
2001;2:1099–108.
50.Storr MA. What is nonacid reflux disease? Can J Gastroenterol
2011;25:35–8.
51.Talley NJ. American Gastroenterological Association medical position
statement: evaluation of dyspepsia. Gastroenterology 2005;129:1753–5.
52.Van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, et al.
Proton pump inhibitors and the risk of colorectal cancer. Am J Gastro­
enterol 2008;103:966–73.
53.Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intra­
esophageal impedance and pH measurement of acid and ­nonacid
gastroesophageal reflux: effect of omeprazole. Gastroenterology
2001;120:1599–606.
54.Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and
non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol
Ther 2003;17:243–51.
55.Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a
meta-analysis. Am J Gastroenterol 2001;96:689–96.
56.Von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for
patients with functional dyspepsia: results of a multicenter, placebocontrolled double-blind study. Am J Gastroenterol 2007;102:1268–75.
57.Werning C (Hrsg.). Medizin für Apotheker. Ein Handbuch mit Grundwissen für die Praxis. 3. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2008.
58.Wilde MI, McTavish D. Omeprazole. An update of its pharmacology
and therapeutic use in acid-related disorders. Drugs 1994;48:91–132.
59.Yip D, Kovac S, Jardine M, et al. Omeprazole-induced interstitial neph­
ritis. J Clin Gastroenterol 1997;25:450–2.